Developing a novel model system to target insulin-reactive CD8 T cells.
CD8 T cells play an important role in autoimmune diabetes development, and therefore removing these cells may protect against disease. To test this, we designed a novel method using engineered cells (InsCD3-zeta) to target insulin-specific CD8 T cells. Insulin-reactive target cells were cultured with InsCD3-zeta CD8 T cells and cytotoxicity was assessed. Activated, but not naïve, InsCD3-zeta CD8 T cells readily killed insulin-reactive target CD8 T cells. This approach to immunotarget relevant pathogenic CD8 T cells may be a therapeutic option to delay or prevent type 1 diabetes.
Scott
Gwen S
GS
Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, Bristol, United Kingdom.
Fishman
Sigal
S
Margalit
Alon
A
Siew
L Khai
LK
Chapman
Stephen
S
Wen
Li
L
Gross
Gideon
G
Wong
F Susan
FS
D000818:Animals; D017252:CD3 Complex / Q000235:genetics; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D003603:Cytotoxins / Q000494:pharmacology / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D004195:Disease Models, Animal; D005260:Female; D007328:Insulin / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D016688:Mice, Inbred NOD; D008822:Mice, Transgenic
D017252:CD3 Complex; C121704:CD3 antigen, zeta chain; D003603:Cytotoxins; D007328:Insulin